wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 8. no 1. March 2003  
 TABLE OF CONTENT

 Original articles
CD16 expression on peripheral blood monocytes in asthma patients after allergen immunotherapy
Krzysztof Kowal1, Joanna Osada2, Milena Dąbrowska2, Anna Bodzenta-Łukaszyk1

1)Klinika Alergologii i Chorób Wewnętrznych, Akademia Medyczna w Białymstoku, ul. Skłodowskiej-Curie 24a, 15-276 Białystok
2)Zakład Diagnostyki Hematologicznej, Akademia Medyczna w Białymstoku, ul. Skłodowskiej-Curie 24a, 15-276 Białystok



Introduction. Recently described subpopulation of peripheral blood monocytes, which express CD16 (CD14/CD16), is characterized by increased antigen presenting ability but decreased production of anti-inflammatory mediators including interleukin-10 (IL-10). Increased percentage of CD14/CD16 cells has been found in peripheral blood of bronchial asthma patients.
Aim of study. The aim of this study was to evaluate the changes in the prevalence of CD14/CD16 cells in the peripheral blood of patients with allergic rhinitis and asthma during the course of immunotherapy (IT) with house dust mite allergen extracts.
Material and methods. The study involved on 23 patients with allergic rhinitis and mild bronchial asthma. 17 patients were treated with IT, while 6 patients received only pharmacotherapy. 10 healthy subjects served as negative controls. IT was performed using Novo Helisen Depot (Allergopharma, Germany). Blood was collected before therapy, 3 months and 12 months after the initiation of IT. Flow cytometry analysis was performed on the whole blood samples using monoclonal antibodies against CD14 and CD16 labeled with FITC and PE respectively (Pharmingen, USA).
Results. Significantly higher percentage of CD14/CD16 cells was found in the peripheral blood of patients with allergic rhinitis and asthma in comparison to healthy controls. In patients treated with IT a decrease in the percentage of CD14/CD16 cells was observed already after 3 months and the changes persisted after 12 months of IT. No significant change in the percentage of CD14/CD16 cells was observed in allergic rhinitis and asthma patients not treated with IT.
Conclusion. Changes in monocyte subpopulations during IT may represent one of the mechanisms of beneficial clinical effect of IT observed in patients suffering from allergic rhinitis and bronchial asthma.
Alergia Astma Immunologia, 2003, 8(1), 33-38


keywords: astma, immunoterapia, CD16, asthma, immunotherapy, CD16

pages: from 33 to 38



estimated time of download (97 kB)
broadband speed:561282565121024[kbps]
time:207432[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.